Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arsenic trioxide - Phebra

Next Previous
X
Search
Drug Profile

Arsenic trioxide - Phebra

Alternative Names: Arsenic trioxide Phebra; ATO - Phebra; Phenasen

Latest Information Update: 28 May 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Phebra
  • Developer Flexipharm Austrading; Phebra
  • Class Anti-inflammatories; Antineoplastics; Arsenicals; Ischaemic heart disorder therapies; Oxides; Skin disorder therapies; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Endothelial cell modulators; Immunostimulants; Thioredoxin reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute promyelocytic leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute promyelocytic leukaemia

Most Recent Events

  • 28 May 2023 No recent reports of development identified for phase-I development in Acute-promyelocytic-leukaemia(First-line therapy) in Australia (PO, Capsule)
  • 28 May 2023 No recent reports of development identified for phase-I development in Acute-promyelocytic-leukaemia(First-line therapy) in New Zealand (PO, Capsule)
  • 21 May 2021 Phase-I development is still ongoing in Acute promyelocytic leukaemia (First-line therapy) in Australia, New Zealand (PO, Capsule) (ACTRN12616001022459)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top